In light of the recent FDA approval of amivantamab and the lack of a systematic review of the relevant literature, this systematic review aimed to examine the efficacy and safety of amivantamab in NSCLC patients with EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.